Human monocyte-derived suppressive cells (HuMoSC) for cell therapy in giant cell arteritis.
cellular therapy
giant cell arteritis
suppressive cells
treatment
vascular remodeling
Journal
Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960
Informations de publication
Date de publication:
2023
2023
Historique:
received:
04
01
2023
accepted:
06
02
2023
entrez:
10
3
2023
pubmed:
11
3
2023
medline:
14
3
2023
Statut:
epublish
Résumé
The pathogenesis of Giant Cell Arteritis (GCA) relies on vascular inflammation and vascular remodeling, the latter being poorly controlled by current treatments. This study aimed to evaluate the effect of a novel cell therapy, Human Monocyte-derived Suppressor Cells (HuMoSC), on inflammation and vascular remodeling to improve GCA treatment. Fragments of temporal arteries (TAs) from GCA patients were cultured alone or in the presence of HuMoSCs or their supernatant. After five days, mRNA expression was measured in the TAs and proteins were measured in culture supernatant. The proliferation and migration capacity of vascular smooth muscle cells (VSMCs) were also analyzed with or without HuMoSC supernatant. Transcripts of genes implicated in vascular inflammation ( Altogether, our results suggest that HuMoSCs or their supernatant could be useful to decrease vascular in flammation and remodeling in GCA, the latter being an unmet need in GCA treatment.
Identifiants
pubmed: 36895571
doi: 10.3389/fimmu.2023.1137794
pmc: PMC9989212
doi:
Substances chimiques
Vascular Endothelial Growth Factor A
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1137794Informations de copyright
Copyright © 2023 Samson, Genet, Corbera-Bellalta, Greigert, Espígol-Frigolé, Gérard, Cladière, Alba-Rovira, Ciudad, Gabrielle, Creuzot-Garcher, Tarris, Martin, Saas, Audia, Bonnotte and Cid.
Déclaration de conflit d'intérêts
MS: Roche–Chugai consulting, AbbVie consulting, Boehringer Ingelheim consulting, Novartis consulting and research grant, VIFOR Pharma consulting; BB: Roche–Chugai personal fees for consulting, Boehringer Ingelheim consulting; CC-G: Horus and Bayer grant, Novartis and Bayer honoraria and Novartis, Bayer, Thea, Horus, Alcon and Allergan medical advisory board; P-HG: Allergan, Bayer and Novartis travel expenses, Novartis and Bayer honoraria; MCC: GlaxoSmithKline consulting, CSL Vifor consulting, AbbVie consulting, Janssen consulting, Astrazeneca consulting, Kiniksa Pharmaceuticals research grant; GE-F: GlaxoSmithKline consulting, Janssen consulting. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Oncoimmunology. 2021 Feb 19;10(1):1880046
pubmed: 33659098
Ann Rheum Dis. 2008 Nov;67(11):1581-8
pubmed: 17584806
J Allergy Clin Immunol. 2015 Jun;135(6):1614-24.e4
pubmed: 25630940
Lancet. 2016 May 7;387(10031):1921-7
pubmed: 26952547
Ann Rheum Dis. 2022 Apr;81(4):524-536
pubmed: 35045965
Ann Rheum Dis. 2014 Mar;73(3):616-23
pubmed: 23625984
Arthritis Rheumatol. 2019 Aug;71(8):1319-1328
pubmed: 30848549
Arthritis Rheumatol. 2017 Apr;69(4):837-845
pubmed: 28133925
Trials. 2021 Aug 17;22(1):543
pubmed: 34404463
Arthritis Rheum. 2007 Aug;56(8):2789-97
pubmed: 17665429
Arthritis Rheum. 2003 Oct 15;49(5):703-8
pubmed: 14558057
Lancet. 2008 Jul 19;372(9634):234-45
pubmed: 18640460
Arthritis Rheum. 2013 Jan;65(1):1-11
pubmed: 23045170
Gene. 2017 May 30;614:1-7
pubmed: 28267575
Front Pharmacol. 2021 Jun 24;12:672150
pubmed: 34248626
Sci Rep. 2017 Jul 26;7(1):6553
pubmed: 28747747
Blood. 2000 Jul 1;96(1):34-40
pubmed: 10891427
Rheumatology (Oxford). 2019 Sep 1;58(9):1639-1643
pubmed: 30915462
Clin Rev Allergy Immunol. 2022 Jan 15;:
pubmed: 35031958
J Korean Med Sci. 2020 Sep 07;35(35):e289
pubmed: 32893519
Autoimmun Rev. 2010 Aug;9(10):635-45
pubmed: 20457278
Autoimmun Rev. 2017 Apr;16(4):398-406
pubmed: 28232168
Ann Rheum Dis. 2022 Jun;81(6):861-867
pubmed: 35190385
N Engl J Med. 2017 Jul 27;377(4):317-328
pubmed: 28745999
Eur J Intern Med. 2018 Apr;50:12-19
pubmed: 29146018
Nat Rev Dis Primers. 2022 Jan 6;7(1):93
pubmed: 34992251
J Clin Med. 2022 May 20;11(10):
pubmed: 35629030
Rheumatology (Oxford). 2006 Nov;45(11):1356-63
pubmed: 16621921
Ann Intern Med. 2001 Jan 16;134(2):106-14
pubmed: 11177313
Ann Rheum Dis. 2022 May;81(5):653-661
pubmed: 35264321
J Autoimmun. 2018 Nov;94:99-109
pubmed: 30061014
Ann Rheum Dis. 2016 Jun;75(6):1177-86
pubmed: 26698852
Rheumatology (Oxford). 2018 Jun 1;57(6):1011-1020
pubmed: 29506143
Autoimmun Rev. 2017 Aug;16(8):833-844
pubmed: 28564617
Ann Rheum Dis. 2017 Sep;76(9):1624-1634
pubmed: 28606962
Ann Rheum Dis. 2010 Feb;69(2):434-42
pubmed: 19289383